---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-072058"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:08:59.810152+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension

## Summary
- AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.
- Secondary endpoint 6MWD also showed no meaningful improvement; LS mean differences ranging -11.7 to +1.3 meters.
- Company halting enrollment and shutting down Phase 3 IMPAHCT and long-term extension study, per advisory committee.
- Cash position ~$100M as of June 15, 2024; CEO calls results unexpected and disappointing.
- Full Phase 2b data release timing to be determined; no new clinical path announced.

## SEC filing metadata
- accession: 0001104659-24-072058
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/0001104659-24-072058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/tm2417394d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-072058
- JSON: https://secwatch.observer/filing/0001104659-24-072058.json
- Plain text: https://secwatch.observer/filing/0001104659-24-072058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.